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Abstract (281 words) 
Type 2 diabetes (T2D) is closely linked with non-alcoholic fatty liver disease (NAFLD) 
and hepatic insulin resistance, but the involved mechanisms are still elusive. Using DNA 
methylome and transcriptome analyses of livers from obese individuals, we found that both 
hypomethylation at a CpG site in PDGFA (encoding platelet derived growth factor alpha) and 
PDGFA overexpression are associated with increased T2D risk, hyperinsulinemia, increased 
insulin resistance and increased steatohepatitis risk. Both genetic risk score studies and human 
cell modeling pointed to a causative impact of high insulin levels on PDGFA CpG site 
hypomethylation, PDGFA overexpression, and increased PDGF-AA secretion from liver. We 
found that PDGF-AA secretion further stimulates its own expression through protein kinase C 
activity and contributes to insulin resistance through decreased expression of both insulin 
receptor substrate 1 and of insulin receptor. Importantly, hepatocyte insulin sensitivity can be 
restored by PDGF-AA blocking antibodies, PDGF receptor inhibitors and by metformin 
opening therapeutic avenues. Conclusion: Therefore, in the liver of obese patients with T2D, 
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the increased PDGF-AA signaling contributes to insulin resistance, opening new therapeutic 
avenues against T2D and NAFLD.  
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In type 2 diabetes (T2D), hepatic insulin resistance is strongly associated with non-
alcoholic fatty liver disease (NAFLD), a condition that hits >70% of diabetic patients (1). 
However, the molecular mechanisms involved are still incompletely understood. Genome-wide 
association studies (GWAS) and related metabolic traits have identified many loci associated 
with the risk of T2D (2). However, these loci only explain 15% of T2D inheritance, and GWAS 
have opened limited insights into the pathophysiology of T2D and its related complications 
including NAFLD (2). Epigenetic analyses of liver have enabled the identification of novel 
metabolic players and associated mechanisms involved in hepatic insulin resistance and 
NAFLD (3). Further, several DNA methylome wide association studies have identified 
candidate genes possibly involved in metabolic dysfunction of the adipose tissue, skeletal 
muscle and liver in obesity and T2D (4–8).  
In this study, we hypothesized that DNA methylome of livers from patients with T2D, 
when compared to livers of individuals with normal plasma glucose levels, can unveil key 
players of hepatic insulin resistance and NAFLD in response to a diabetogenic environment. 
Our DNA methylome and transcriptome wide association analyses for T2D in liver samples 
from obese subjects identified a reduced methylation of a CpG site within the platelet-derived 
growth factor A gene (PDGFA), which was consistent with an increase in PDGFA mRNA. 
PDGFA encodes a protein forming a PDGF-AA homodimer, which is known as a liver fibrosis 
factor when overexpressed in the liver (9). We found that the rise of liver PDGFA is not only 
associated with increased T2D risk, but also with increased steatohepatitis (NASH) risk, 
increased fasting insulin levels and increased insulin resistance. The increased PDGFA 
expression and PDGF-AA protein levels were reproduced in human hepatocytes made insulin-
resistant by long-term insulin incubation, and were present in the liver of insulin-resistant 
rodents. Furthermore, we have demonstrated the role of elevated PDGF-AA in perpetuating 
hepatocyte insulin resistance via a vicious autocrine negative feedback loop.  
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Experimental procedure  
Discovery study. Liver biopsies were collected from 192 subjects from the French obesity 
surgery. Subjects included in the discovery study were participants of the ABOS (“Atlas 
Biologique de l'Obésité Sévère”) cohort (ClinicalGov NCT01129297) including 750 morbidly 
obese subjects whose several tissues were collected during bariatric surgery (10). All subjects 
were unrelated, women, above 35 years of age, of European origin verified by Principal 
Component Analysis (PCA) using SNPs on the Metabochip array, non-smoker, non-drinker, 
without any history of hepatitis, and without indications of liver damage in serological analysis 
(normal ranges of aspartate aminotransferase, alanine aminotransferase and gamma-glutamyl 
transpeptidase). Overall, 96 T2D cases and 96 normoglycemic participants were selected. 
Normoglycemia and T2D were defined using the World Health Organization/International 
Diabetes Federation 2006 criteria (Normoglycemia: fasting plasma glucose < 6.1 mmol/l or 2-
h plasma glucose < 7.8 mmol/l; T2D: fasting plasma glucose ≥ 7 mmol/l or 2-h plasma glucose 
≥ 11 mmol/l). Each participant of the ABOS cohort signed an informed consent. For calculation 
of intermediate metabolic traits (HOMA2-IR and HOMA2-B indexes), see the supplemental 
information. All procedures were approved by local ethics committees. The main clinical 
characteristics were presented in Table S1. 
Replication study. The replication study was based on in silico data of liver samples analyzed 
by the Infinium HumanMethylation450 BeadChip, as previously reported (11). Clinical 
characteristics were reported in Table S2. Liver samples were obtained percutaneously from 
subjects undergoing liver biopsy for suspected nonalcoholic fatty liver disease or 
intraoperatively for assessment of liver histology. Normal control samples were recruited from 
samples obtained for exclusion of liver malignancy during major oncological surgery. None of 
the normal control subjects underwent preoperative chemotherapy, and liver histology 
7 
 
demonstrated absence of both cirrhosis and malignancy. Consenting subjects underwent a 
routine liver biopsy during bariatric surgery for assessment of liver affection. Biopsies were 
immediately frozen in liquid nitrogen, ensuring an ex vivo time of less than 40 seconds in all 
cases. A percutaneous follow-up biopsy was obtained in consenting bariatric patients five to 
nine months after surgery. Patients with evidence of viral hepatitis, hemochromatosis, or 
alcohol consumption greater than 20 g/day for women and 30 g/day for men were excluded. All 
patients provided written, informed consent. The study protocol was approved by the 
institutional review board (‘‘Ethikkommission der Medizinischen Fakultät der Universität 
Kiel,’’ D425/07, A111/99) before the beginning of the study. 
Epigenome-wide DNA methylation profiling. The epigenome-wide analysis of DNA 
methylation was performed using the Infinium HumanMethylation450 BeadChip (Illumina, 
Inc., San Diego, CA, USA) which interrogates 482,421 CpG sites and 3,091 non-CpG sites 
covering 21,231 RefSeq genes (12). We used 500ng of DNA from liver tissue for bisulfate 
conversion using the EZ DNA Methylation kit D5001 (Zymo Research, Orange, CA, USA) 
according to the manufacturer’s instructions. For the details of procedure, see the supplemental 
information. 
SNP genotyping, ethnic characterization and genetic risk score. SNP genotyping was 
performed with Metabochip DNA arrays (custom iSelect-Illumina genotyping arrays) using the 
Illumina HiScan technology and GenomeStudio software (Illumina, San Diego, CA, USA) (13). 
We selected SNPs with a call rate ≥ 95 % and with no departures from Hardy–Weinberg 
equilibrium (p>10-4). A Principal Component Analysis (PCA) was performed in a combined 
dataset involving the 192 patients plus 272 subjects from the publicly available HapMap project 
database. For details of analysis, see the supplemental information. 
8 
 
Statistical Analyses. Statistical analysis and quality control were performed with R software 
version 3.1.1. Raw data (IDAT file format) from Infinium HumanMethylation450 BeadChips 
were imported into R using the minfi package (version 1.12.0 on Bioconductor) (14), then we 
applied the preprocessing method from GenomeStudio software (Illumina) using the reverse 
engineered function provided in the minfi package. Samples were excluded when less than 75 
% of the markers had detection p-values below 10-16. Markers were ruled out when less than 95 
% of the samples had detection p-values below 10-16. According to this strategy, no sample was 
excluded and 70,314 markers (over 485,512) were excluded. For correction for Infinium 
HumanMethylation450 BeadChip design which includes two probe types (Type I and Type II), 
a Beta-MIxture Quantile normalization (BMIQ) was performed (15). Moreover, we checked 
for outliers using Principal Component Analysis (PCA) (flashpcaR package, version 1.6-2 on 
CRAN). At this stage, 416,693 markers and 192 samples were kept for further analysis. To test 
the association between methylation level and diabetic status, we applied a linear regression 
adjusted for steatosis (in percent), presence of NASH and fibrosis. Results were corrected for 
multiple testing using a Bonferroni correction (p<10-7). The association between DNA 
methylation and metabolic traits was analyzed using a linear regression model, including 
normoglycemic samples adjusted for age and BMI. Quality control was performed on the 
HumanHT-12 v4.0 Whole-Genome DASL HT Assay (Illumina) data, according to the 
following criterion: probes were kept for further analysis when the detection p-values provided 
by GenomeStudio software version 3.0 (Illumina) were below five percent for all samples. A 
PCA was performed to identify samples with extreme transcriptomic profiles. After the quality 
control just described, 18,412 probes matching 13,664 genes and 187 samples were kept and 
analyzed for differential expression between T2D cases and controls, using linear regression. 
To account for multiple testing, we used five percent as a threshold for false discovery rate 
(FDR). Methylation and expression data were tested for correlation.  
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We selected a subgroup of 24 samples among the 192 initial samples, including 12 
normoglycemic and 12 T2D cases, to analyze DNA methylation in blood samples from the 
same donors. The 24 samples were selected based on their expression and methylation profiles 
using PCA to reduce the heterogeneity.  
Cell Culture. Immortalized Human Hepatocytes (IHH) were cultured in Williams E medium 
(Invitrogen), containing 11 mM glucose and supplemented with 10 % fetal calf serum (FCS; 
Eurobio), 100 U/ml penicillin, 100 μg/ml streptomycin, 20 mU/ml insulin (Sigma-Aldrich) and 
50 nM dexamethasone (Sigma-Aldrich) (16). For insulin pre-treatment, 106 cells were cultured 
in 6-well plates in a Dulbecco’s Modified Eagle Medium (DMEM; Invitrogen) with or without 
100 nM human insulin (Novo Nordisk) supplemented with 5 mM Glucose, 2 % FCS, 100 U/ml 
penicillin, 100 µg/ml streptomycin for 24 hours. For monitoring insulin signaling, medium was 
removed and replaced by FCS- and phenol red-free DMEM medium with or without 200 nM 
human insulin for one hour. Human hepatocytes were isolated from liver lobectomies resected 
for medical reasons as described (17) in agreement with the ethics procedures and adequate 
authorization. 
RNA sequencing, Microarray mRNA expression analysis, qRT-PCR, Western Blotting, 
Chemicals, ELISA, Glycogen measurement, Global Serine/Threonine kinases activity, 
DNA/RNA preparation, Oil-Red staining, cell proliferation, apoptosis, intermediate 
metabolic traits. See the supplemental experimental procedure in the supplemental 
information 
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Results 
Liver epigenetic modification in T2D  
The liver DNA methylome was assessed in 96 age and body mass index (BMI)-matched 
obese women with T2D and 96 obese women with normal glucose levels (Table S1). While we 
initially identified 381 differentially methylated regions (DMRs) in the liver from obese patients 
with T2D compared to normal glucose obese patients (Fig. S1), we only observed one genome-
wide significant DMR (cg14496282 within PDGFA) in obese patients with T2D after adjusting 
for liver steatosis and NASH, in an attempt to control for liver cellularity and impairment 
severity. The methylation at cg14496282 was associated with decreased T2D risk (β = -15.6 %; 
p = 2.5×10-8; Fig. 1a and 1b). The average DNA methylation at the cg14496282 was 41.3 % 
in patients with T2D and 60.3 % in controls, which corresponds to a 1.46-fold decrease in the 
methylation level of the CpG site. We checked the methylation, at this CpG site, for possible 
confounding effects due to differences in cell composition (18), and we still observed consistent 
effects for T2D risk (β = -14.9 %; p = 6.9×10-7). We replicated this association in the liver from 
12 German cases with T2D and 53 German control subjects (11), and found that T2D risk was 
associated with decreased methylation level at cg14496282 site (β = -14.0 %; p = 0.01) (Table 
S2). These data were also supported by a recent study showing a decrease in PDGFA 
methylation in the liver from obese men with T2D compared to non-obese controls (4).  
We next investigated whether the T2D-associated PDGFA cg14496282 
hypomethylation was specific to the liver. We assessed the blood DNA methylome from 12 
obese cases with T2D and 12 obese normal glucose controls presenting with extreme liver 
methylation levels at cg14496282. We found a significant correlation between methylation 
levels in blood and liver (r = 0.66; p = 6.61×10-4), and a slightly reduced methylation at the 
cg14496282 site (β = -1.4 %; p = 0.01) in blood of subjects with T2D when compared to 
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controls. We also compared DNA methylation at cg14496282 in 43 liver and skeletal muscle 
samples from 192 participants who were randomly selected, but we did not find any significant 
correlation (p > 0.05).  
In the 192 obese liver samples, we next investigated cis-located genes (within 500 kb 
around cg14496282) that were differentially expressed between T2D cases and controls, and 
which mRNA expression correlated with DNA methylation at PDGFA cg14496282 site. Using 
a false discovery rate threshold of 5 % for differential expression analysis and methylation-
expression correlation analysis, we identified that the methylation at cg14496282 is negatively 
associated with the expression of PDGFA in T2D cases and normal glucose controls (p < 0.007; 
Table 1).  
Reduced liver PDGFA expression is associated with lower hepatic fibrosis risk  
In subjects with T2D and in normoglycemic controls, we found that PDGFA 
cg14496282 methylation was significantly associated with decreased NASH risk (p < 0.05; 
Table 1), while PDGFA expression in the liver was associated with increased NASH risk (p < 
0.01; Table 1). Furthermore, in patients with T2D, PDGFA cg14496282 methylation was 
significantly associated with decreased hepatic fibrosis, decreased alanine aminotransferase 
levels and decreased aspartate aminotransferase levels (p < 0.05; Table 1), while PDGFA 
expression in the liver was associated with increased hepatic fibrosis and increased liver 
enzyme levels (p < 0.01; Table 1). These results were in line with previous studies that showed 
that PDGFA cg14496282 hypomethylation is associated with increased PDGFA liver 
expression in advanced versus mild human NAFLD (19,20). PDGFA encodes a dimer disulfide-
linked polypeptide (PDGF-AA) that plays a crucial role in organogenesis and cirrhotic liver 
regeneration (21,22). Overexpression of PDGF-AA in mice liver causes spontaneous liver 
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fibrosis (9). Moreover, activation of PDGF receptor signaling stimulates hepatic stellate cells 
and thereby, promotes liver fibrosis (23–25).  
Increased liver PDGFA expression is associated with hyperinsulinemia and insulin 
resistance  
In obese subjects with normal glucose levels, we next found that PDGFA cg14496282 
methylation is significantly associated with decreased fasting serum insulin levels and 
decreased insulin resistance as modeled by the homeostasis model assessment index HOMA2-
IR (β = -1.45×10-3, p = 2.32×10-3; and β = -0.10, p = 4.93×10-3, respectively; Table 1). In 
contrast, PDGFA liver expression was significantly associated with increased fasting serum 
insulin levels and increased insulin resistance (β = 6.83×10-3, p = 9.49×10-3; and β = 0.53, p = 
7.47×10-3, respectively; Table 1).  
Subsequently, we calculated a genetic risk score (GRS) as the sum of alleles increasing 
fasting insulin levels over 19 GWAS-identified single nucleotide polymorphisms (SNPs) (26), 
and found that this GRS is associated with decreased DNA methylation at cg14496282 (β = -
1.05 % per allele; p = 4×10-3; Table S3). This association remained significant when we 
analyzed T2D cases and controls separately (and then meta-analyzed) or when we adjusted for 
BMI, high-density lipoprotein (HDL) cholesterol or triglycerides; these traits having a genetic 
overlap with fasting insulin (26). These results strongly suggested that hyperinsulinemia (and 
associated insulin resistance) contributes to decreased DNA methylation of PDGFA 
cg14496282 and consequently to the increase in the PDGFA expression. In contrast, the GRS 
including 24 SNPs associated with fasting glucose, the GRS including 65 SNPs associated with 
T2D and the GRS including 97 SNPs associated with BMI were not associated with 
cg14496282 methylation (Table S3), which excluded that hyperglycemia and obesity per se 
are directly modulating PDGFA methylation and expression.  
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The in vivo association between liver PDGFA overexpression and insulin resistance was 
supported by data obtained in different mice models of insulin resistance associated with 
obesity. In the liver from C57BL/6J (B6) mice that are susceptible to diet-induced obesity (27), 
we found that Pdgfa expression is increased by 46 %, as compared with control mice (i.e. that 
do not respond to a high-fat diet) (Fig. 1c). Similarly, we found that liver Pdgfa expression is 
increased in insulin resistant BXD mice fed a high-fat diet for 21 weeks when compared to 
control mice (Fig. 1d). However, the cg14496282 CpG site is not conserved in mice (28), 
suggesting that different epigenetic mechanisms rely on the rise of Pdgfa/PDGFA in insulin-
resistant hepatocytes in mice and humans. 
Increased PDGFA expression and secretion from insulin-resistant human hepatocytes  
The association of increased liver PDGFA expression with insulin resistance in obese 
subjects suggests that PDGFA overexpression plays a role in liver insulin resistance, and 
therefore in T2D development. Chronic hyperinsulinemia indeed induces liver insulin 
resistance (29) and PDGFA has an autocrine function on hepatocytes (20). In this context, the 
exposure of mouse embryo cells to PDGF-AA inhibits insulin signaling (30). Therefore, we 
hypothesized that the obesity-associated increased PDGFA expression contributes to mediate 
the deleterious effects of chronic hyperinsulinemia on hepatic insulin resistance. To assess this 
hypothesis, we established an in vitro model of insulin-resistant human hepatocytes caused by 
hyperinsulinemia. To do so, we used the immortalized human hepatocytes (IHH). IHH cells are 
indeed equipped will the functional machinery for glucose metabolism (15) and they secrete 
PDGF-AA homodimer at comparable levels with primary human hepatocytes (Fig. 2a). 
Exposure of IHH cells to insulin for 16 h or 24 h hampered insulin-induced phosphorylation of 
AKT serine/threonine kinase at residue serine 473 (Fig. 2b). In line with AKT activation pivotal 
role in glycogen synthesis (31), we found reduced insulin-induced glycogen production in IHH 
cells exposed to insulin for 16 h and 24 h (Fig. 2c). The defective insulin signaling by insulin 
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was accompanied by a rise in PDGFA mRNA, and in abundance and secretion of the encoded 
protein PDGF-AA homodimer from IHH cells (Fig. 2d-f). In addition, the insulin-induced 
increase in PDGFA expression was associated with the reduced cg14496282 CpG methylation 
level in IHH cells (Fig. 2g), suggesting that insulin resistance induced by hyperinsulinemia 
accounts for the rise of PDGFA in hepatocytes of obese individuals with diabetes. As these 
results may be cell line dependent, we measured AKT phosphorylation in liver hepatocellular 
HepG2 cells exposed to insulin for 24 h and retrieved similar results (Fig. 2h). In HepG2 cells, 
the expression of PDGFA was also significantly increased after long-term insulin incubation 
(Fig. 2i). The increase in PDGFA mRNA seemed specific to insulin exposure as neither cell 
proliferation (Fig. S2) nor the intracellular neutral lipid levels was modified by insulin treatment 
(Fig. S3). On the other hand, palmitate exposure did not change PDGFA expression in IHH 
cells (Fig. S3). Our data suggest that it is chronic hyperinsulinemia and not the excess of fatty 
acid influx that induces PDGF-AA secretion in the liver of obese individuals with T2D.  
PDGF-AA contributes to insulin resistance induced by insulin  
We then hypothesized that PDGF-AA directly causes insulin resistance in human 
hepatocytes. In line with this hypothesis, we found that the culture of IHH cells with a human 
PDGF-AA recombinant inhibits insulin-induced AKT activation (Fig. 3a). In contrast, the 
incubation of IHH cells with anti-PDGF-AA blocking antibodies reversed the deleterious effect 
of insulin long term exposure on AKT phosphorylation (Fig. 3b). We then investigated the 
mechanism whereby PDGF-AA inhibits AKT activation. Human hepatocytes express PDGF 
receptors (PDGFR) including PDGFR and PDGFR that both bind PDGF-AA (22). We tested 
the role of PDGFR signaling using the PDGFR inhibitor Ki11502 (32). Pre-treatment of IHH 
cells with Ki11502 efficiently antagonized the negative effect of insulin on AKT 
phosphorylation mimicking results obtained with PDGF-AA blocking antibodies (Fig. 3c). 
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PDGFR blockade by Ki11502 increased the ability of insulin to stimulate glycogen synthesis 
(Fig. 3d).  
To further dissect the signaling pathways by which both insulin and PDGF-AA impair 
AKT and insulin action, we performed a global measurement of serine/threonine protein 
kinases (STKs) using STK PamGene arrays consisting of 140 immobilized serine/threonine-
containing peptides that are targets of most known kinases (33). We looked for differential STK 
activity between control and IHH cells cultured with insulin for 24 h. Peptides whose 
phosphorylation varied significantly between the two conditions were indicative of differential 
specific STK activities. This unbiased kinase analyses underscored significant differences in 
protein kinases C (PKCƟ and PKC) activities (Fig. 4a). The activation of these two PKCs 
hampers insulin signaling in response to chronic hyperlipidemia (34–36). These two kinases 
are also known to phosphorylate the insulin receptor substrate 1 (IRS1) and the insulin receptor 
(INSR) on serine residues, that impairs the association of INSR with IRS proteins, leading to 
the blockade of AKT activation and of the downstream signaling pathways (35, 36). Therefore, 
we treated IHH cells with phorbol 12-myristate 13-actetate (PMA), a potent activator of PKCs, 
and retrieved AKT inhibition (Fig. S4). PKCƟ and PKC kinase activities are linked to their 
phosphorylation at Serine 676 and Serine 729, respectively (37,38). In IHH cells cultured with 
insulin for 16 h or 24 h, we found a striking phosphorylation of the two PKCs, which coincided 
with the decreased AKT phosphorylation (Fig. 4b). The effect of insulin on the phosphorylation 
of the two kinases is likely to rely on PDGF-AA, as the PKCƟ and PKC were directly activated 
by PDGF-AA (Fig. 4c). Activation of PKC decreases INSR abundance (34). In line with this 
result, we found in IHH cells cultured with insulin and PDGF-AA that an impaired INSR 
content is closely linked to reduced INSR tyrosine phosphorylation at residue Y972 (Fig. 4d). 
Inversely the PKC mediated-threonine phosphorylation 1376 which inactivates the INSR, was 
increased in response to insulin or PDGF-AA (Fig. 4e).  
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To gain further insights into the intracellular mechanism through which PDGF-AA 
alters insulin signaling in hepatocytes, we performed RNA sequencing of IHH cells treated or 
not with insulin for 24 h. We found a profound dysregulation of expression of genes involved 
in both carbohydrate metabolism, inflammatory and insulin signaling pathways in response to 
insulin. Indeed, when we grew a network based on PDGFA through Ingenuity Pathway 
Analysis (IPA), we found a significant increase in the expression of genes of the VEGF and 
PDGF families, including as expected PDGFA (log2 Fold Change = 0.80; p = 1.1×10-11) (Fig. 
S5 and Table S4). Subsequently, we analyzed the diseases and/or functions highlighted by the 
insulin-evoked deregulated expressed genes in IHH cells. Among the significant outputs, we 
found a network related to the metabolism of carbohydrates that includes PDGFA (p = 1.2×10-
6; Fig. S5, Table S4). We also identified in IHH cells cultured with insulin for 24 h a decrease 
in the expression of the insulin receptor substrate 1 (IRS1) gene (Fig. 5a, Fig. S5 and Table 
S5). The decreased IRS1 expression by insulin was confirmed by western blotting (Fig. 5b) and 
mimicked by PDGF-AA (Fig. 5c). Silencing of IRS1 expression using small interfering RNAs 
confirmed that the IRS1 abundance is critical for AKT activation in IHH cells in response to 
insulin (Fig. 5d). Defective IRS1 level can therefore account for the impaired insulin signaling 
caused by PDGF-AA in insulin resistant hepatocytes. The decrease of IRS1 is mediated by PKC 
activity since its inhibition by the PKCƟ and PKC, inhibitor sotrastaurin (39) prevented the 
reduction of IRS1 caused by hyperinsulinemia (Fig. 5e), and in contrast, PKC activation by 
(PMA) mimicked the effect of insulin (Fig. 5f). 
Altogether, our data suggest a role for hepatocyte PDGF-AA in promoting further liver 
insulin resistance via the decrease of INSR and IRS1, and the activation of both PKCƟ and 
PKC.  
Autocrine regulation of PDGF-AA on its expression and the beneficial effects of 
metformin 
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PDGF-AA stimulates its own expression in the liver (40). It suggests that in insulin 
resistant hepatocytes PDGF-AA amplifies its secretion, thereby perpetuating insulin resistance. 
We found that culture of IHH cells with PDGF-AA stimulated PDGFA expression (Fig. 6a) 
and PDGF-AA secretion (Fig. S6). The effect of PDGF-AA on its expression was mediated by 
PDGFR as the PDGFR tyrosine kinase inhibitor ki11502 prevented the rise of PDGFA mRNA 
of cells exposed to either insulin or to human PDGF-AA (Fig. 6b and 6c). The overexpression 
of PDGFA by PDGF-AA may require PKC activation since the PMA mimicked both insulin 
and PDGF-AA effects on the PDGFA mRNA (Fig. 6d) and inversely, the inhibitor sotrastaurin, 
alleviated the rise of PDGFA (Fig. 6e). Altogether, it is likely that in T2D, hyperinsulinemia-
induced PDGF-AA aggravates its overexpression and its consequences (Fig. 6f). The most 
prescribed T2D drug metformin inhibits PKC (41) and has been specifically proposed for 
diabetic patients with NAFLD and hepatocarcinoma (HCC) (42). Furthermore, metformin 
reduces HCC incidence in diabetic patients in a dose-dependent manner (43). We found that 
metformin also efficiently abolished the expression of insulin-induced PDGFA mRNA (Fig. 
7a), protein content (Fig. 7b) and secretion (Fig. 7c). Thus, a part of the effects of metformin 
on insulin sensitivity may be mediated by the reduction of PDGFA overexpression in 
hepatocytes.  
 
Discussion 
GWAS have only identified so far few genes involved in NAFLD (44) and the contribution of 
epigenetics to T2D liver dysfunction is still elusive. While we initially identified 381 
differentially methylated regions (DMRs) in the liver from obese patients with T2D compared 
to normal glucose obese patients, we only observed one genome-wide significant DMR 
(cg14496282 within PDGFA), associated with the increase of PDGFA expression in cis, in 
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obese patients with T2D after adjusting for liver steatosis and NASH. It suggests that the other 
DMRs are a consequence rather than a cause of the early stages of NAFLD. On the contrary, 
cg14496282 might be instrumental in the functional impairment of the liver in obesity 
associated T2D. Notably, we found that liver PDGFA cg14496282 hypomethylation and 
concomitant rise in liver PDGFA expression were also associated with systemic insulin 
resistance in non-diabetic obese patients but not with their glucose values. Elevated PDGFA 
expression was also reported in biliary atresia (45), and is a diagnostic and prognostic biomarker 
of cholangiocarcinoma that is a liver cancer associated with severe insulin resistance (but 
paradoxically not with obesity) (32, 46). Thus, PDGFA seems to be a liver marker of insulin 
resistance and of chronic hyperinsulinemia. Furthermore, the genetic data from our analysis of 
GRS related to insulin resistance, suggest a causative effect of plasma insulin levels on 
methylation level, hepatic expression and secretion of this growth factor. Therefore, the 
elevated PDGFA expression in human liver from obese subjects can be directly due to their 
severe hyperinsulinemia.   
PDGFA encodes a dimer disulfide-linked polypeptide (PDGF-AA) that plays a crucial role in 
organogenesis (20). The overactivation of the PDGF-AA receptor signaling is involved in 
cirrhotic liver regeneration (21) and the chronic elevation of PDGF-AA in mice liver induces 
fibrosis (22). High PDGF-AA levels contribute to hepatic fibrogenesis by activating hepatic 
stellate cells in mice (23–25). In human, the association of increased PDGFA expression with 
liver steatosis and fibrosis observed in our study and in others supports a similar fibrogenic role 
in human liver (18,19), in which chronic hyperinsulinemia might be instrumental (47). We also 
believe that PDGF-AA contributes to the inhibitory effect of chronic hyperinsulinemia on 
hepatocyte insulin signaling via a feedback autocrine loop (Fig. 6f). We indeed showed that 
PDGF-AA stimulates its own induction via the activation of PKC. This vicious cycle 
perpetuates high PDGF-AA level and thereby worsens liver insulin resistance. Our data further 
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suggests that the negative effect of PDGF-AA on insulin signaling is the consequence of the 
decrease of IRS1 and INSR, and PKC activation including PKCƟ and PKC. These two kinases 
are known to phosphorylate IRS-1 and the insulin receptor on serine residues, that impairs the 
association of the insulin receptor with IRS proteins, leading to the blockade of AKT activation 
and of the downstream signaling (35,36).  
Our findings may have a major interest for the treatment of T2D and of its hepatic 
complications. We showed that metformin, the most-widely prescribed oral insulin sensitizer 
agent prevented the PDGF-AA insulin-induced vicious circle. Metformin has been specifically 
proposed for diabetic patients with NAFLD and hepatocarcinoma (HCC) (42). Metformin 
reduces the risk of HCC incidence in diabetic patients in a dose-dependent manner (43). 
Thereby metformin may improve liver insulin sensitivity at least in part through PDGF-AA 
liver blockade, explaining its long-term effect against HCC. Beside liver insulin sensitizers, 
blocking PDGF-AA activity may be a promising alternative anti-diabetic therapeutic. The anti-
tumor PDGFR inhibitor imatinib demonstrated unexpected (and unexplained until now) 
improvement of insulin sensitivity in insulin-resistant rats (48) as well as a dramatic blood-
glucose-lowering effect in diabetic subjects treated for leukemia (49,50).  
Our study also suggests that human epigenome analysis, when directly performed in 
disease-affected tissues is an efficient tool to make progress in the pathogenesis of common 
diseases. Furthermore, it opens avenues in the identification of new drug targets to combat T2D, 
and complications linked to insulin resistance, including NAFLD and cancer.  
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Legends of Figures 
Fig. 1. a) Quantile-quantile (qq-) plot showing the residual inflation of test statistics before and 
after genomic-control correction. b) Manhattan plot centered on PDGFA cg14496282 
methylation site showing association signal within PDGFA bounds. Hepatic Pdgfa expression 
in c) 6 weeks old male B6 mice that were diet-induced obese (DIO) responder (Resp, black 
circle) and DIO-non-responder (nResp, white circle) and in d) in BXD mice fed on Chow diet 
(CD, green circle) or a HFD (black circle) fed for 21 weeks. *** indicates p value < 0.0001 by 
unpaired t test with Welch’s correction.  
 
Fig. 2. a) PDGF-AA secretion from IHH cells and primary human hepatocytes was measured 
by ELISA kit. b) Measurement of insulin-induced AKT phosphorylation in response to human 
insulin (NovoNordisk) for the indicated times. IHH cells were incubated in a culture medium 
containing 5 mM Glucose, 2 % FCS with or without 100 nM human insulin for the indicated 
times. AKT phosphorylation was stimulated by 200 nM insulin for one hour. Immunoblotting 
for phospho-AKT (P-AKT) was done using the anti phospho-AKT (Serine 473) antibodies. The 
Fig. shows the result of a representative experiment out of three. c) Effect of insulin on the 
glycogen production. Insulin-induced glycogen production was measured by ELISA in IHH 
cells that were pre-cultured with 100 nM insulin for 16 h and 24 h. d) Increase of PDGFA 
mRNA by insulin. IHH cells were cultured with 100 nM human insulin for 16 h and 24 h. The 
PDGFA mRNA level was quantified by qRT-PCR and normalized against GUSB. The 
expression levels from untreated cells were set to 100 %. Data are the mean  SEM (**: p < 
0.001). e) PDGF-AA abundance in IHH cells cultured with insulin. IHH cells were cultured 
with 100 nM human insulin for the indicated times. PDGF-AA content was quantified by 
Western Blotting experiments. The blot is one representative out of three independent 
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experiments. f) PDGF-AA secretion in response to insulin. IHH cells were cultured with insulin 
for the indicated times. The measurement of PDGF-AA from the supernatant was achieved by 
ELISA. g) Methylation levels at PDGFA cg14496282 in response to insulin. IHH cells were 
cultured in a culture medium containing 5 mM Glucose, 2 % FCS with or without 100 nM 
human insulin for 24 h. Methylation level at the cg14496282 was quantified by the Infinium 
HumanMethylation450 BeadChip. h) Effect of chronic insulin in Insulin-induced AKT 
activation in HepG2 cells. HepG2 cells were incubated in a culture medium with 100 nM human 
insulin or without (Ctl) for 24 h. AKT phosphorylation was stimulated by 200 nM insulin for 
one hour. Immunoblotting for phospho-AKT (P-AKT) was done using the anti phospho-AKT 
(Serine 473) antibodies. The Fig. shows the result of a representative experiment out of three. 
i) Increase of PDGFA mRNA by insulin in HepG2 cells. The PDGFA mRNA level was 
quantified by qRT-PCR in HepG2 and IHH cells that were cultured with insulin for 24 h. The 
PDGFA mRNA was normalized against GUSB. The expression levels from untreated cells were 
set to 100 %. Data are the mean  SEM (**: p < 0.001). 
 
Fig. 3. Effects of a) human PDGF-AA recombinant, b) PDGFA blocking antibodies or c) the 
PDGFR inhibitor ki11502 on insulin-induced AKT activation. Activation of AKT was 
monitored by western blotting using total proteins from IHH cells that were cultured with the 
human recombinant PDGF-AA at the indicated concentrations for 24 h, which subsequently 
were incubated with 200 nM insulin for stimulating AKT phosphorylation. For a-c, IHH cells 
were co-incubated in a culture medium containing 5 mM Glucose, 2 % FCS with or without 
100 nM human insulin for 24 hours plus a) PDGF-AA at the indicated concentration, b) 
PDGFA antibodies (+; 0.75 g or ++; 1.5 g) or c) ki11502 at the indicated concentration. The 
Figures show the result of a representative experiment out of three. d) Effect of the PDGFR 
inhibitor ki11502 on the glycogen production. Glycogen was measured by ELISA in IHH cells 
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that were co-cultured with 5 M ki11502 and insulin for the indicated times. Glycogen was 
monitored after stimulating cells in a KRP buffer without (Ctrl) or with insulin for 1 hr and 20 
mM glucose. Glycogen was monitored by ELISA.  
 
Fig. 4: a) Volcano plot showing differences in putative serine/threonine kinase activities 
between control and insulin-treated IHH cells for 24 hrs. Specific and positive kinase statistic 
(in red) show higher activity in IHH cultured with insulin compared with control samples. 
Effects of b) insulin and c) PDGF-AA on the phosphorylation of PKCƟ and PKC. IHH cells 
were cultured with insulin for the indicated times or PDGF-AA (for 24 hrs). Phosphorylation 
of PKCƟ (Ser 676) and PKC (Ser 729) were measured by western blotting and normalized 
against total PKCƟ and PKC. d) Effect of insulin and PDGF-AA on the tyrosine 
phosphorylation (Y972) of INSR (p-IR) and threonine phosphorylation of INSR (T1375), INSR 
abundance (IR) and Tubulin. Western Blotting experiments were achieved from total proteins 
of IHH cells cultured either with 100 nM insulin of 100 ng/ml PDGF-AA for 24 hr. 
Phosphorylation of INSR was done by stimulating IHH cells with insulin for 1 h. The Figures 
show the result of a representative experiment out of three. 
 
Fig. 5: Effect of insulin on a) IRS1 mRNA level and b) protein. The IRS1 mRNA level and 
IRS1 abundance was quantified by qRT-PCR and Western Blotting in IHH cells cultured with 
100 nM insulin for 24 h. The IRS1 mRNA was normalized against RPLP0. The expression 
levels from untreated cells were set to 100 %. Data are the mean  SEM (**: p < 0.001). c) 
effect of PDGF-AA on the IRS1 content. IHH cells were cultured with PDGF-AA at the 
indicated concentrations for 24 h. The Figures show the result of a representative experiment 
out of three. d) Effect of siRNA against IRS1 on the insulin-induced AKT activation. Duplexes 
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of small interfering RNAs were transfected in IHH cells for 48h. Thereafter, AKT 
phosphorylation on the serine 473 was induced with insulin for 1 h. The Figures show the result 
of a representative experiment out of three. Effect of e) the PKC inhibitor sotraustorin PKC and 
f) phorbol 12-myristate 13-acetate (PMA) PKC activator on the expression of IRS1 mRNA. 
PDGFA mRNA was quantified in IHH cells cultured with either sotrastaurin at the indicated 
concentration in the presence of 100 nM insulin for 24 h, or PMA for the indicated times. The 
IRS1 mRNA was normalized against RPLP0. The expression levels from untreated cells were 
set to 100 %. Data are the mean  SEM (***: p < 0.0001).  
 
Fig. 6: Effect of Ki11502 PDGFR inhibitor on the PDGFA expression in response to a) PDGF-
AA and b) insulin. IHH cells were cultured for 24 h with 100 ng/ml PDGF-AA or 100 nM 
insulin in the presence or absence of 5 M ki11502 for 24 h. Effect of c) PKC activator phorbol 
12-myristate 13-acetate (PMA) and d-e) the PKC inhibitor sotraustorin on the expression of 
PDGFA mRNA.The PDGFA mRNA was quantified by qRT-PCR in IHH cells cultured with 
either PMA for the indicated times, or 100 nM insulin or 100 ng/ml PDGF-AA in the presence 
of 1 M sotrastaurin or at the indicated concentration for 24 hrs. The PDGFA mRNA was 
normalized against RPLP0. The expression levels from untreated cells were set to 100 %. Data 
are the mean  SEM (*, p<0.05; ***: p < 0.0001). f) Schematic representation of the mechanism 
linking hyperinsulinemia to hepatic insulin resistance in T2D. Insulin promotes 
hypomethylation and the rise of PDGFA expression, leading to PDGF-AA secretion. In turn, 
PDGF-AA inhibits the insulin signaling, in a negative autocrine feedback loop, via a mechanism 
involving a decrease in the IRS1 and INSR abundance and PKC (PKCƟ and PKC) activation. 
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Fig. 7: Effect of metformin on the a) PDGFA mRNA level and PDGF-AA b) intracellular 
abundance and c) PDGF-AA secretion induced by 100 nM insulin for the indicated times. 
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Supplemental Experimental Procedures 
 
Microarray mRNA expression analysis. Transcriptome profiling was performed using the 
HumanHT-12 v4.0 Whole-Genome DASL HT Assay (Illumina). Total RNA was converted to 
cDNA using biotinylated oligo-dT18 and random nonamer primers, followed by 
immobilization to a streptavidin-coated solid support. The biotinylated cDNAs were then 
simultaneously annealed to a set of assay-specific oligonucleotides based on content derived 
from the National Center for Biotechnology Information (NCBI) Reference Sequence Database 
(release 98). The extension and ligation of the annealed oligonucleotides generate PCR 
templates that are then amplified using fluorescently-labeled (P1) and biotinylated (P2) 
universal primers. The labeled PCR products were captured on streptavidin paramagnetic 
beads, to yield single-stranded fluorescent molecules which were then hybridized, via gene-
specific complementarity, to the HumanHT-12 BeadChip, thereafter fluorescence intensity was 
measured for each bead. Hybridized chips were scanned by using iScan (Illumina) and raw 
measurements were extracted by GenomeStudio software version 3.0 (Illumina). 
 
Epigenome-wide DNA methylation profiling. Bisulfite converted DNA was amplified, 
fragmented and hybridized to the BeadChips following the standard Infinium protocol. All the 
samples were randomized across the chips and analyzed on the same machine by the same 
technician to reduce batch effects. After single base extension and staining, the BeadChips were 
imaged with the Illumina iScan. Raw fluorescence intensities of the scanned images were 
extracted with the GenomeStudio (V2011.1) Methylation module (1.9.0) (Illumina). The 
fluorescence intensity ratio was used to calculate the β-value which corresponds to the 
methylation score for each analyzed site according to the following equation: β-
value = intensity of the Methylated allele (M) / (intensity of the Unmethylated allele (U) + 
intensity of the Methylated allele (M) + 100). DNA methylation β-values range from zero 
(completely unmethylated) to one (completely methylated). All samples had high bisulfite 
conversion efficiency (signal intensity >4000) and were included for further analysis based on 
GenomeStudio quality control steps where control probes for staining, hybridization, extension 
and specificity were examined. The intensity of both sample dependent and sample independent 
built in controls was checked for the red and green channels using GenomeStudio. 
 
 
Intermediate metabolic traits. Body mass index (BMI) is the weight in kilograms divided by 
the square of the height in meters. The HOMA2-IR and HOMA2-B indexes were calculated 
using the HOMA (HOmeostasis Model Assessment) calculator based on fasting glucose and 
fasting insulin levels in subjects in steady-state situation (available at 
http://www.dtu.ox.ac.uk/homacalculator). We also calculated the Quantitative Insulin 
Sensitivity Check Index (QUICKI) using fasting glucose and fasting insulin levels (available at 
https://sasl.unibas.ch/11calculators-QUICKI.php). The degree of steatosis was defined as the 
percentage of hepatocytes containing fat droplets. In the control group of normoglycemic 
samples, the association levels reported in our study cannot be influenced by T2D treatment.  
 
SNP genotyping, ethnic characterization and genetic risk score. For HapMap, 272 subjects 
including 87 of European ancestries [HapMap CEU], 97 of Asian ancestries [HapMap CHB] 
and 88 of African ancestries [HapMap YRI]) genotype calls at the 106,470 SNPs present on the 
Metabochip were available. The first two components were sufficient to discriminate ethnic 
origin (Fig. S7) and we observed that study participants clustered well with HapMap samples 
of European ancestries. We used 19 SNPs previously established for their association with 
fasting insulin to assess the possibility of causal direct link between DNA methylation at 
cg14496282. These 19 SNPs were on the Metabochip and all passed our quality control. These 
SNPs as well as the associated insulin raising alleles are reported in Table S3. We assessed the 
combined effect of these SNPs on DNA methylation using either fixed-effect meta-analysis and 
by testing the association of DNA methylation at cg14496282 with a genetic risk score (GRS) 
defined for each individual as the count of the number of fasting insulin raising alleles. We also 
tested the association between three other GRS (T2D, BMI and fasting glucose raising alleles) 
and DNA methylation at cg14496282 and expression in Table S6. 
 
DNA and RNA isolation. The DNA samples were isolated using the Gentra Puregene Tissue 
Kit (Qiagen, Les Ulis, France). In order to improve isolation, DNA was then resuspended in 
Tris/Hcl/EDTA buffer and precipitated by adding chloroform:isoamyl alcohol (4 %). Purity 
was determined by using a NanoDrop (NanoDrop Technologies, Wilmington, USA) and 
concentration was determined by using the Qubit® dsDNA BR Assay Kit (Life Technologies 
a brand of Thermo Fisher Scientific, Saint Aubin, France). The RNeasy® Lipid Tissue kit 
(Qiagen) and QIAamp RNA Blood Mini Kit (Qiagen) were used to isolate RNA from liver 
tissue and blood, respectively. Quality and integrity were tested on 2100 Bioanalyzer 
Instruments by using a RNA 6000 Nanochip (Agilent Technologies, Les Ulis, France). 
Concentration was determined by using the Qubit® RNA BR Assay Kit (Life Technologies). 
 
 
Oil Red O staining. IHH cells were grown in a 24-well plate (at an initial density of 105 
cells/well) and incubated with 100 nM insulin for 16 hrs and 24 hrs. Cells were then washed 
three times with iced PBS and fixed with 4% paraformaldehyde for 30 minutes. After fixation, 
cells were washed three times and stained with Oil Red O solution for 15 min at room 
temperature. For Oil Red O content levels quantification, DMSO was added to sample; after 
shaking at room temperature for 5 min, the density of samples was read at 490 nm on a 
spectrophotometer 
 
Cell proliferation and apoptosis. IHH cells were cultured with 100 nM insulin at different 
incubation times. Cell number was counted by trypan blue and apoptosis was determined by 
scoring cells displaying pycnotic or fragmented nuclei (visualized with Hoechst 33342). The 
counting was performed blind by two different experimenters. 
 
RNA-sequencing. RNA samples with a RNA integrity number higher than 9.0 were extracted 
from IHH cells treated or not with 200 nM insulin for 24 hours, from at least three independent 
experiments. RNA libraries were prepared using the TruSeq Stranded mRNA Library 
Preparation Kit (Illumina, San Diego, CA, USA) following the manufacturer’s instructions. The 
libraries were sequenced with the NextSeq 500 (Illumina). A mean of 50 million paired-end 
reads of 100 bp were generated for each sample. More than 92% of the reads for each library 
were effectively mapped to the hg19 human genome assembly using TopHat2. Subsequently, 
both quantification and annotation of the reads were performed using Rsubread. Finally, the 
differential gene expression analyses (i.e. 24 h insulin-treated IHH cells versus IHH cells at 
baseline) were performed using DESeq2. The differentially expressed genes were subjected to 
Ingenuity Pathway Analysis (Qiagen, Hilden, Germany) to decipher the major biological 
pathways and diseases emphasized by the significantly deregulated genes (with a p-value < 
0.05).  
 
PamChip peptide microarrays for kinome analysis. kinome analysis was achieved using 
Serine Threonine Kinases microarrays, which were purchased from PamGene International BV. 
Each array contained 140 target peptides as well as 4 control peptides. Sample incubation, 
detection, and analysis were performed in a PamStation 12 according to the manufacturer’s 
instructions. Briefly, extracts from IHH cells cultured with insulin for 24 hours were made using 
M-PER mammalian extraction buffer (Thermo Scientific) for 20 minutes on ice. The lysates 
were then centrifuged at 15,871 g for 20 minutes to remove all debris. The supernatant was 
aliquoted, snap-frozen in liquid nitrogen, and stored at –80°C until further processing. Prior to 
incubation with the kinase reaction mix, the arrays were blocked with 2% BSA in water for 30 
cycles and washed 3 times with PK assay buffer. Kinase reactions were performed for 1 hour 
with 5 μg of total extract for the mouse experiment or 2.5 μg of total extract for the mature 
adipocyte and 400 μM ATP at 30°C. Phosphorylated peptides were detected with an anti-
rabbit–FITC antibody that recognizes a pool of anti–phospho serine/threonine antibodies. The 
instrument contains a 12-bit CCD camera suitable for imaging of FITC-labeled arrays. The 
images obtained from the phosphorylated arrays were quantified using the BioNavigator 
software (PamGene International BV), and the list of peptides whose phosphorylation was 
significantly different between control and test conditions was uploaded to GeneGo for pathway 
analysis.  
 
Animal experiments. The animal welfare committees of the DIfE as well as the local 
authorities (LUGV, Brandenburg, Germany) approved all animal experiments (reference 
number V3-2347-37-2011 and 2347-28-2014). All mice were housed in temperature controlled 
room (22±1 °C) on a 12:12 h light dark cycle (light on at 6:00 am) and had free access to food 
and water at any time. C57BL/6J breeding pairs (Charles River, Germany) as well as 
NZO/HIBomDife breeding mice (Dr. Kluge, German Institute of Human Nutrition, Germany) 
received a standard chow (SD; V153x R/M-H, Ssniff).  
After weaning male C57BL/6J mice were fed a HFD (60 kcal% fat, D12492, Research Diets) 
ad libitum in groups of two to six animals per cage. Weekly body weight measurements were 
performed in the morning (8-10 am). Classification of mice either prone or resistant to diet-
induced obesity was described before [Kammel et al. 2016 - PMID: 27126637]. At the age of 
6 weeks, mice were killed after 6 h fasting. All tissues were directly frozen in liquid nitrogen 
and stored at -80 °C until further processing. 
Female NZO mice received a standard chow after weaning and starting with 5 weeks of age, 
mice were switched to HFD containing 60 kcal% fat (D12492, Research Diets). Classification 
of diabetes-resistant (DR) mice in week 10 is based on assessment of liver density by computed 
tomography (LaTheta LCT-200, Hitachi-Aloka) combined with the measurement of blood 
glucose (CONTOUR® Glucometer, Bayer) [Lubura et al. 2015 - PMID: 26487005]. Liver 
density <55.2 Hounsfield units and blood glucose values of >8.8 and <16.6 mM both measured 
in week 10 predict later onset of diabetes with 83% and 84% probability, respectively. 
Combination of both parameters increased the prediction probability to 90 %. 
Expression analysis. Total RNA from liver was isolated using QIAzol Lysis Reagent and 
RNeasy Mini Kit as recommended. Residual DNA was removed by DNase digestion using the 
RNase-Free DNase Set (QIAGEN). Subsequently, cDNA synthesis was conducted with 1 µg 
RNA, random hexamer primer as well as oligo(dT)15 primer and M-MLV reverse transcriptase 
(Promega). qRT-PCR was performed with 12.5 ng cDNA in an Applied Biosystems 7500 Fast 
Real-time PCR system with PrimeTime® qPCR Probe Assay (IDT) for Pdgfa and the GoTaq® 
Probe qPCR Master Mix (Promega). Data were normalized to the expression of Eef2 (TaqMan 
Gene Expression Assay, Life Technologies) as endogenous control. For genome expression 
profile either 4x44K or 8x60K whole mouse genome microarrays (Agilent Technologies) were 
used. 
 Immunoblots analysis. Proteins (40 μg) were subjected to SDS-PAGE analysis on 10% gels 
and transferred to nitrocellulose membranes. Rabbit polyclonal for total Akt, phospho-Akt (Ser-
473 and Thr-308) were purchased from Cell Signaling. Monoclonal mouse β actin (clone AC-
74; Sigma-Aldrich) was used as loading control.  
 
Primer sequences. Primers for human PDGFA (sense 5′- GACCAGGACGGTCATTTACG -
3′; antisense 5′- CGCACTCCAAATGCTCCT-3′). Primers for mouse Pdgfa (sense 5′- 
CAAGACCAGGACGGTCATTT -3′; antisense 5′- GATGGTCTGGGTTCAGGTTG-3′). 
Primers for human RPLP0 (sense 5′- ACCTCCTTTTTCCAGGCTTT -3′; antisense 5′- 
CCCACTTTGTCTCCAGTCTTG -3′). Primers for human IRS1 (sense 5′- 
ACAGGCTTGGGCACGAGT-3′; antisense 5′- AGACCCTCCTCTGGGTAGGA -3′) 
 
Glycogen measurement. Total glycogen in IHH cells was determined by using Abcam 
Glycogen assay kit according to the manufacturer’s instruction. The glycogen content was 
determined by using fluorometric assay and the fluorescence was measured using plate reader. 
Corrections for background glucose were made in all the samples and the corrected fluorescent 
readings were applied to standard curve and amount of glycogen in each well was determined. 
The glycogen content of each sample was normalized to their respective protein content and 
plotted using Graph Pad Prism 5 
 
Materials. The PDGFRα inhibitor Ki11502, human PDGF-AA recombinant, Phorbol 12-
Myristate 13-myristate (PMA) and Metformin were purchased from Sigma-Aldrich. The anti-
PDGF-AA blocking antibodies were from Merckmillipore. The PKC inhibitor Sautrostaurin 
was from Selleckchem. 
Quantitative PCR. Total RNA was extracted from IHH cells according to the manufacturer’s 
protocol (RNeasy Lipid Tissue Kit, Qiagen). The RNA purity and concentration were 
determined by RNA Integrity Number (RNA 6000 Nano Kit, 2100 Bioanalyser, Agilent). Total 
RNA was transcribed into cDNA as described (17). Each cDNA sample was quantified by 
quantitative real-time polymerase chain reaction using the fluorescent TaqMan 5′-nuclease 
assays or a BioRad MyiQ Single-Color Real-Time PCR Detection System using the BioRad iQ 
SYBR Green Supermix, with 100 nM primers and 1 µl of template per 20 µl of PCR and an 
annealing temperature of 60 °C. Gene expression analysis was normalized against Beta-
Glucuronidase (GUSB) expression or 60S acidic ribosomal protein P0 (RPLP0). The primer 
sequences are available in the supplemental information. 
Western Blotting and ELISA. Cells were scrapped in cold PBS buffer and then cells pellet 
was incubated for 30 minutes on ice in the following lysis buffer (20 mM Tris acetate pH 7, 
0.27 mM Sucrose, 1% Triton X-100, 1 mM EDTA, 1 mM EGTA, 1 mM DTT) supplemented 
with antiproteases and antiphosphatases (Roche, Meylan, France). Cell lysate was centrifuged 
15 minutes at 18,000g and supernatant was collected as total proteins. For Western blotting 
experiments, 40 µg of total protein extract was separated on 10% SDS-Polyacrylamide gel and 
electrically blotted to nitrocellulose membrane. The proteins were detected after an overnight 
incubation of the membrane at 4°C with the specific primary antibodies against AKT (Santa 
Cruz Biotechnology, dilution 1:1000), PKCƟ (Abcam, dilution 1:1000), PKC (Abcam, 
dilution 1:1000), IRS1 (Cell Signaling Biotechnology, dilution 1:1000), PDGF-AA (Merck 
Millipore, dilution 1:1000), tubulin (Sigma, dilution 1:5000), phospho-AKT (Ser-473; Cell 
Signaling Biotechnology, dilution 1:1000), phospho-PKCƟ (Ser-676, Abcam, dilution 1:1000), 
phospho-PKC (Ser-729, Abcam, dilution 1:1000), phospho-INSR (Tyr-972 and Thr-1375, 
Abcam, dilution 1:1000) in buffer containing 0.1% Tween 20 with either five percent BSA or 
five percent milk (forTubulin). Proteins were visualized with IRDye800 or IRDye700 
(Eurobio) as secondary antibodies. Quantification was performed using the Odyssey Infrared 
Imaging System (Eurobio). PDGFA released in the cell supernatant was quantified by ELISA 
kit (R &D Systems) according to the manufacturer’s protocol. 
 
Controls (n=96) T2D cases (n=96)
Traits (unit) Mean (SD) or n (%) Mean (SD) or n (%) p-value
cg14496282 methylation (%) 60.3% (17.2%) 41.3% (12.2%) 9.27×10-16
PDGFA expression (SD) 0.79
(0.35)
1.04
(0.40)
1.7×10-6
Age (years) 46.7
(7.0)
48.2
(6.3)
0.13
BMI (kg/m²) 47.1
(7.4)
49.1
(7.5)
0.06
Fasting glucose (mmol/l) 5.2
(0.4)
8.5
(3.2)
2.2×10-19
Fasting insulin (pmol/l) 78.7
(36.497)
270.5
(854.2)
0.029
HOMA2-B (unitless) 112.6
(34.8)
71.5
(42.4)
4.67×10-11
HOMA2-IR (unitless) 1.5
(0.7)
2.1
(1.435)
8.0×10-5
QUICKI (unitless) 0.34
(0.03)
0.31
(0.04)
3.83×10-7
Steatosis (%) 21.3%
(20.1%)
42.4%
(23.8%)
4.77×10-10
NASH* (Yes/ No) 4
(4.2%)
17
(18%)
4.44×10-3
Hepatic fibrosis* (Yes/ No) 21
(22%)
45
(47%)
6.55×10-4
Alanine aminotransferase (UI/L)
27.11
(15.8)
34.3
(19.8)
6.04×10-3
Aspartate aminotransferase (UI/L)
22.344
(7.04)
26.9
(14.3)
5.5×10-3
Table S1. Clinical characteristics of the 192 samples (96 cases + 96 controls) included in the discovery cohort. Quantitative traits were compared
between cases and controls using unadjusted linear regression and binary traits* were compared using Fisher exact test.
Controls (n=53) T2D cases (n=12)
Traits (unit) Mean (SD) or n (%) Mean (SD) or n (%) p-value
cg14496282 methylation (%) 63.3%
(19.2%)
41.4%
(11.6%)
3.59×10-4
Age (years) 46.7
(13)
54.6
(13)
0.063
Sex (female)* 42
(79.2%)
5
(71.4%)
0.014
BMI (kg/m²) 40.5
(13.6)
43.2
(11.5)
0.542
Table S2. Clinical characteristics of the 65 selected samples (12 cases + 53 controls) used for replication. Quantitative traits were
compared between cases and controls using unadjusted linear regression and binary traits* were compared using Fisher exact
test.
SNP
Closest gene (locus) Fasting insulin raising allele Effect size
(p-value)
in Controls
Effect size (p-value)
in T2D cases
I2
statistic
(p-value)
Fixed effect meta-analysis
effect size
(p-value)
rs459193
ANKRD55
MAP3K1
G
-1.85
( 0.483 )
-0.87
( 0.691 )
0%
( 0.776 )
-1.27% ( 0.448 )
rs4865796 ARL15 A
-3.53
( 0.216 )
0.96
( 0.656 )
37.49%
( 0.206 )
-0.68% ( 0.692 )
rs3822072 FAM13A1 A
-2.89
( 0.267 )
0.12
( 0.953 )
0%
( 0.353 )
-0.97% ( 0.532 )
rs1421085 FTO C
-0.66
( 0.794 )
-2.83
( 0.124 )
0%
( 0.486 )
-2.09% ( 0.158 )
rs10195252
GRB14
COBLL1
T
-0.27
( 0.913 )
0.22
( 0.91 )
0%
( 0.876 )
0.03% ( 0.983 )
rs1167800 HIP1 A
2.31
( 0.414 )
0.54
( 0.793 )
0%
( 0.611 )
1.15% ( 0.486 )
rs2943645 IRS1 T
-1.66
( 0.552 )
-0.73
( 0.698 )
0%
( 0.783 )
-1.02% ( 0.511 )
rs4846565 LYPLAL1 G
-6.69
( 0.006 )
1.49
( 0.483 )
85.03%
( 0.01 )
-2.15% ( 0.171 )
rs6822892 PDGFC A
-0.88
( 0.731 )
-1.03
( 0.62 )
0%
( 0.963 )
-0.97% ( 0.546 )
rs731839 PEPD G
-3.69
( 0.197 )
-0.95
( 0.643 )
0% ( 0.432 ) -1.88% ( 0.256 )
rs17036328 PPARG T
-6.3
( 0.122 )
-4.42
( 0.115 )
0%
( 0.701 )
-5.02% ( 0.028 )
rs2126259 PPP1R3B T
-0.24
( 0.96 )
-2.54
( 0.418 )
0%
( 0.69 )
-1.86% ( 0.477 )
rs2745353 RSPO3 T
-4.72
( 0.056 )
-1.23
( 0.546 )
17.56%
( 0.271 )
-2.66% ( 0.088 )
rs7903146 TCF7L2 C
-1.66
( 0.619 )
-2.75
( 0.172 )
0%
( 0.78 )
-2.46% ( 0.15 )
rs974801 TET2 G
4.32
( 0.141 )
-2.37
( 0.229 )
72.58%
( 0.056 )
-0.29% ( 0.861 )
rs6912327 UHRF1BP1 T
-1.68
( 0.576 )
-3.87
( 0.064 )
0%
( 0.546 )
-3.16% ( 0.062 )
rs1530559 YSK4 A
3.94
( 0.154 )
-1.71
( 0.356 )
65.92%
( 0.087 )
0.05% ( 0.974 )
rs860598 IGF1 A
-5.39
( 0.118 )
3.6
( 0.095 )
79.95%
( 0.026 )
1.09% ( 0.548 )
rs780094 GCKR C
0.21
( 0.936 )
1.35
( 0.513 )
0%
( 0.736 )
0.92% ( 0.569 )
Overall
Meta-analysis
(Cases +
Controls)
- -
-1.63%
(0.011)
-0.83%
(0.079)
2.4%
(0.428)
-1.11%
(0.004)
Genetic Risk
Score (GRS)
- -
-1.68%
(0.010)
-0.74%
(0.099) 30.2% (0.231)
-1.05%
(0.004)
Table S3. Association between fasting insulin raising alleles and DNA methylation at cg14496282. Associations were assessed using linear regression with
methylation as response variable. All models were adjusted for age, BMI, total cholesterol, HDL cholesterol, triglycerides and fasting glucose. Effect sizes are
reported as percentage of DNA methylation per allele.
Gene Log2 Fold Change p-value
PDGFRB -0.68 3.2E-10
IL1RN -0.59 3.0E-15
A2M -0.33 2.2E-09
FGF2 -0.31 9.5E-03
VDR -0.25 3.2E-02
PRKACB -0.25 1.7E-03
IRS1 -0.21 1.1E-02
POU5F1 -0.19 6.0E-03
NFATC2 -0.17 2.7E-02
NR3C1 -0.14 4.4E-02
PRKACA -0.13 2.1E-02
PDPK1 -0.13 1.8E-02
HDAC1 -0.12 3.9E-02
RXRB -0.12 4.2E-02
PRKAR1A -0.12 2.4E-02
SP1 -0.11 3.9E-02
NME2 0.11 2.6E-02
SSRP1 0.12 2.2E-02
SPP1 0.12 1.6E-02
NCL 0.12 8.2E-03
TAF4 0.16 8.2E-03
NFKB1 0.17 2.8E-03
FURIN 0.18 4.5E-02
VEGFB 0.20 1.5E-02
PDAP1 0.21 3.0E-03
HIF1A 0.22 6.4E-05
TGFB1 0.23 3.0E-04
MAP2K1 0.23 1.3E-04
MAP2K2 0.23 1.1E-02
DNM2 0.25 1.7E-04
RRAS 0.25 4.4E-02
TNFRSF1A 0.25 7.6E-06
GRB14 0.26 2.2E-02
NFIC 0.27 1.3E-02
NME1 0.28 1.1E-06
IL18 0.29 3.1E-02
PDGFB 0.43 1.2E-04
PCSK5 0.52 8.3E-12
EDN1 0.55 6.4E-05
VEGFA 0.56 5.8E-13
NES 0.64 1.2E-25
DUSP1 0.67 9.7E-11
PDGFA 0.80 1.1E-11
KLF5 0.87 3.6E-13
EGR1 1.13 2.2E-16
Table S4. List of deregulated genes within the network of PDGFA
Gene Log2 Fold
Change p-value Gene
Log2 Fold
Change p-value Gene
Log2 Fold
Change p-value
G6PC -1,69 2,3E-36 FAS -0,14 2,3E-02 TCF7L2 0,24 5,7E-04
PDGFRB -0,68 3,2E-10 CPT1A -0,14 1,9E-02 OAS1 0,25 2,3E-03
IL1RN -0,59 3,0E-15 ALG2 -0,14 1,2E-02 SREBF1 0,25 8,4E-03
GPAM -0,54 1,5E-18 ACADM -0,14 2,2E-02 TIGAR 0,25 5,1E-04
SLC2A2 -0,53 3,8E-14 PIGF -0,14 3,5E-02 HEXB 0,25 1,1E-05
CREB3L3 -0,51 1,8E-05 CHKB -0,13 4,7E-02 ITGB1 0,25 6,3E-06
ENPP2 -0,47 2,5E-04 GM2A -0,13 3,2E-02 TNFRSF1A 0,25 7,6E-06
GNMT -0,47 2,9E-04 PDPK1 -0,13 1,8E-02 CTGF 0,25 7,8E-03
PPARGC1A -0,46 1,3E-08 EXTL2 -0,12 4,2E-02 CHST6 0,26 2,9E-02
ETNK2 -0,44 1,3E-09 PHKB -0,12 3,5E-02 UGP2 0,26 3,0E-04
SLC23A2 -0,41 2,2E-14 NAGA -0,12 3,9E-02 GCNT3 0,26 5,4E-04
SH3YL1 -0,39 6,4E-07 MAN2A1 -0,11 4,8E-02 B3GNT3 0,27 8,0E-05
PXYLP1 -0,38 4,9E-04 B3GAT1 -0,11 3,5E-02 GYS1 0,27 4,5E-05
CYP3A5 -0,35 6,1E-03 PGM3 -0,10 4,3E-02 ADRBK1 0,28 2,0E-04
TRPV1 -0,35 2,0E-05 NQO1 0,10 4,6E-02 CSF1 0,29 3,5E-03
PGAP1 -0,34 1,7E-05 RHOA 0,10 3,8E-02 IL18 0,29 3,1E-02
PMM1 -0,34 3,0E-06 CLTC 0,10 4,5E-02 GPI 0,29 2,4E-08
NEU3 -0,33 7,4E-05 XBP1 0,10 2,9E-02 NR1D1 0,30 3,1E-03
PPP1R3F -0,31 9,2E-03 SCD 0,11 3,6E-02 GAL 0,30 2,7E-02
ST6GAL1 -0,31 3,2E-10 SPP1 0,12 1,6E-02 B4GALNT1 0,30 5,2E-04
FGF2 -0,31 9,5E-03 PTGFRN 0,12 4,5E-02 SFN 0,31 1,5E-03
GALNT7 -0,29 3,6E-02 GNB1 0,12 5,2E-03 TPI1 0,31 5,5E-07
RGN -0,29 1,6E-05 PTEN 0,13 3,5E-02 HBEGF 0,31 2,1E-02
PIGV -0,27 9,9E-05 SH3KBP1 0,13 2,9E-02 IGF2 0,32 8,2E-05
SLC37A4 -0,27 1,2E-07 DSE 0,13 4,8E-02 GOT1 0,33 4,0E-07
PPARA -0,27 4,3E-05 GALE 0,13 1,8E-02 SLC2A8 0,33 2,3E-04
GALT -0,25 9,8E-05 AFF4 0,13 4,2E-02 PPARG 0,33 2,7E-04
IGF1R -0,25 1,8E-05 PRPS1 0,13 3,0E-02 CHSY1 0,34 6,5E-08
NDST2 -0,25 1,2E-04 CDC42 0,14 1,5E-02 GMDS 0,36 1,5E-09
C5 -0,25 2,0E-04 SLC9A3R1 0,14 3,1E-02 PPP1R3C 0,37 1,8E-04
GCKR -0,25 1,0E-03 TALDO1 0,14 7,0E-03 NTSR1 0,37 4,9E-03
ONECUT1 -0,25 3,3E-02 ARF6 0,15 7,0E-03 GBE1 0,38 8,8E-06
LIPC -0,25 5,7E-03 RPE 0,15 1,7E-02 DKK1 0,39 8,5E-08
GPLD1 -0,24 2,4E-03 GNPDA1 0,15 1,3E-02 SERINC2 0,39 3,3E-05
ENPP1 -0,24 3,9E-05 GK 0,15 4,2E-02 FOXA2 0,39 2,8E-07
NDST1 -0,24 7,4E-04 GLA 0,15 1,3E-02 PKM 0,40 1,6E-12
CTBS -0,22 9,4E-03 SH3GLB1 0,16 1,1E-02 PLCH2 0,40 3,5E-03
H6PD -0,22 8,5E-04 PYGB 0,16 3,0E-02 PGK1 0,42 5,4E-07
IRS1 -0,21 1,1E-02 HS2ST1 0,17 4,7E-03 PLAU 0,43 9,5E-04
ALDH5A1 -0,21 2,8E-04 GNE 0,17 6,1E-03 PDGFB 0,43 1,2E-04
S1PR2 -0,21 3,0E-02 CEBPB 0,17 3,6E-02 PLA2G3 0,44 5,4E-04
KHK -0,21 3,6E-03 XYLT1 0,17 3,2E-02 PPP1R3G 0,45 1,6E-04
HDAC5 -0,20 3,4E-03 COQ2 0,17 2,2E-02 STBD1 0,45 2,6E-06
PPP1R3E -0,20 2,2E-03 NFKB1 0,17 2,8E-03 ALDOA 0,45 6,8E-11
SIAE -0,20 7,8E-04 FOXO1 0,18 2,4E-02 ICAM1 0,45 1,2E-17
PLCD1 -0,20 4,9E-02 G6PD 0,18 3,0E-02 ALDOC 0,46 1,3E-10
CHPT1 -0,19 6,3E-04 FUCA2 0,18 8,3E-04 DUSP6 0,46 2,0E-15
PIGZ -0,19 2,9E-02 TKT 0,18 8,3E-03 SLC2A1 0,49 1,3E-18
SLC5A2 -0,19 1,8E-02 MTMR2 0,19 3,9E-03 GRB10 0,49 1,8E-06
CHST3 -0,17 1,4E-03 GYG1 0,19 5,5E-03 PFKP 0,52 3,8E-09
EPHX1 -0,17 3,3E-03 INPP5E 0,19 3,9E-02 AGPAT2 0,53 3,1E-06
FUCA1 -0,17 1,3E-02 ADORA2B 0,20 1,2E-02 SLC16A3 0,54 2,7E-10
LCAT -0,17 4,3E-02 MYC 0,20 2,3E-04 EDN1 0,55 6,4E-05
PIGP -0,16 3,2E-02 TRPV2 0,20 3,7E-03 ANGPTL8 0,56 1,6E-06
SULF2 -0,16 3,1E-02 NEU1 0,21 1,5E-05 HK1 0,57 2,1E-05
SERINC5 -0,16 2,6E-02 GAPDH 0,21 1,5E-04 CHST15 0,62 1,6E-10
TGFBR1 -0,16 1,3E-02 PLCG2 0,21 2,7E-02 CEMIP 0,71 1,7E-20
HECTD4 -0,16 4,8E-02 PRKAA2 0,21 2,2E-03 PFKFB3 0,71 1,3E-07
DYRK2 -0,16 2,8E-02 HS6ST1 0,22 7,7E-03 IGFBP3 0,78 1,4E-08
CPS1 -0,15 1,1E-02 HIF1A 0,22 6,4E-05 PPP1R15A 0,80 3,5E-19
PLCB1 -0,15 2,7E-02 PFKFB2 0,22 5,3E-04 PDGFA 0,80 1,1E-11
EPM2AIP1 -0,15 1,2E-02 CHKA 0,22 1,9E-05 HK2 0,82 8,4E-23
SRD5A3 -0,14 3,9E-02 TGFB1 0,23 3,0E-04 NR4A1 0,86 1,0E-21
PLSCR1 -0,14 2,9E-02
Table S5. List of deregulated genes within the network related to the metabolism of carbohydrates
Table S6. Correlation between multiple genetic risk scores (GRS) and PDGFA methylation in
192 ABOS study participants. GRS are calculated as the number of trait/risk increasing alleles
over NSNP (number of SNPs) independent loci.
Traits Publication identifying genome-
wide associated SNPs
Correlation between 
GRS and PDFGA DNA 
methylation 
at cg14496282
(p-value)
Type 2 diabetes 
(NSNP=65) Morris et al. 
Nat. Genet. (2012)
-0.07 
(0.32)
BMI 
(NSNP =97)
Locke et al. 
Nature (2015)
-0.01 
(0.87) 
Fasting glucose 
(NSNP =24)
Vaxillaire et al. 
Diabetologia (2014)
-0.05 
(0.51)
Fasting insulin 
(NSNP =19)
Scott et al. 
Nat. Genet. (2012)
-0.21 
(0.005)
Fig. S1. CpG sites differentially methylated in livers of obese diabetic vs normoglycemic individuals. Liver methylome of 192
individuals revealed 381 differentially methylated CpG sites in 96 obese diabetic vs 96 normoglycemic.
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Fig. S2. Cell proliferation and death in response to insulin. IHH Cells were cultured with 100 nM insulin for the indicated times. a) Cell
number and b) apoptosis were counted.
O
il
R
e
d
O
 a
b
s
o
rb
a
n
c
e
 (
O
D
4
9
0
 n
M
)
0
1
2
Insulin 100 nM
Ctrl
16hrs 24hrs
p-AKT
AKT
Ctrl
Insulin
Palmitate
- + - +
0
50
100
150
200
m
R
N
A
le
v
e
l
P
D
G
F
A
(%
 o
f 
c
o
n
tr
o
l)
Ctrl Palmitate
a
b
Fig. S3. Role of lipids in IHH cells a) Lipid accumulation in IHH cells. Cells were cultured with 100 nM insulin for the indicated times. Intracellular
fat drops were read with spectrophotometer at 490 nm with Oil Red O staining, representing the mean ± SD of 3 independent experiments. b) effect of
palmitate on the PDGFA mRNA level. IHH cells were cultured with 0.5 mM Palmitate (coupled to BSA) for 24 hrs. Impaired insulin-induced Akt
activation was monitored by western blotting experiments (upper panel) using the anti-phospho-AKT (Thr-308) and anti-Akt antibodies. The The
PDGFA mRNA level was quantified by qRT-PCR and normalized against GUSB. The expression levels from untreated cells were set to 100 %. Data
are the mean  SEM (n=3 independent experiments).
Fig. S4. Effect of PMA on a) insulin-induced AKT activation. IHH cells were incubated in a culture medium containing 5
mM Glucose, 2 % FCS with or without 100 nM human insulin and 125 ng/ml PMA for 30 minutes. Immunoblotting was done
using the anti-phospho-AKT (Thr-308), anti-AKT and anti aTubulin antibodies.
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Fig. S5. a) Dysregulated genes within the network of PDGFA. Red and green colors mean increased and decreased gene expression, respectively. Solid lines
embody direct interaction, while dotted lines embody indirect interactions. b) Dysregulated genes within the network related to the carbohydrates metabolism.
Red and green colors mean increased and decreased gene expression, respectively. Each line embodies a predicted relationship: an orange line leads to activation,
a blue line leads to inhibition, a yellow line highlights that the findings are inconsistent with state of downstream molecule, and a gray line highlight that the effect is
not predicted.
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Fig. S6. Effect of exogenous PDGF-AA on the PDGF-AA secretion. IHH cells were cultured with 100 ng/ml human PDGF-
AA or vehicle (Ctrl) for 24 hrs. PDGF-AA in the supernatant was measured by ELISA.
Fig. S7. HapMap samples of European ancestries. Principal component analysis on a combined dataset including
192 study participants and 272 samples from HapMap Project database and showing that study participants clustered
well with HapMap samples of European ancestries (CEU).
